Compare Haemonetics Corp. with Similar Stocks
Dashboard
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.96
Poor long term growth as Net Sales has grown by an annual rate of 7.32% and Operating profit at 8.03% over the last 5 years
Flat results in Jun 25
With ROCE of 12.30%, it has a attractive valuation with a 2.47 Enterprise value to Capital Employed
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 3,282 Million (Small Cap)
22.00
NA
0.00%
1.09
19.68%
3.86
Total Returns (Price + Dividend) 
Haemonetics Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics
Haemonetics Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation, with its stock price at $68.36. Over the past year, the company has faced challenges, posting a -21.00% return, contrasting with the S&P 500's 12.65% gain. Key financial metrics indicate a competitive position despite stock volatility.
Read full news article Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 110 Schemes (53.14%)
Held by 142 Foreign Institutions (16.63%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is -2.78% vs -5.14% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is -41.38% vs 54.67% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 3.95% vs 12.01% in Mar 2024
YoY Growth in year ended Mar 2025 is 42.60% vs 1.91% in Mar 2024






